PMV Pharmaceuticals (PMVP) Cash & Current Investments (2019 - 2026)

PMV Pharmaceuticals (PMVP) has 8 years of Cash & Current Investments data on file, last reported at $93.5 million in Q1 2026.

• Quarterly Cash & Current Investments fell 41.73% year-over-year to $93.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.5 million (down 41.73% YoY) and the FY2025 annual result came in at $112.8 million, down 33.4% from the prior year.
• Cash & Current Investments slipped to $93.5 million in Q1 2026, from $112.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $229.4 million in Q1 2023 to a low of $38.5 million in Q4 2023.
• A 5-year average of $126.9 million and a median of $115.1 million in 2022 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 339.82% in 2024, down 78.87% in 2024.
• Tracing PMVP's Cash & Current Investments over 5 years: stood at $109.1 million in 2022, then sank by 64.69% to $38.5 million in 2023, then jumped by 339.82% to $169.5 million in 2024, then slumped by 33.4% to $112.8 million in 2025, then declined by 17.18% to $93.5 million in 2026.
• The last three Cash & Current Investments figures came in at $93.5 million (Q1 2026), $112.8 million (Q4 2025), and $129.2 million (Q3 2025), per Business Quant data.